Orthofix International

Orthofix Medical, Inc. engages in the provision of medical devices. It operates through the following business segments: Global Spine and Global Extremities. The Global Spine reporting segment offers three primary product categories: Bone Growth Therapies, Spinal Implants, and Biologics. The Bone Growth Therapies product category manufactures, distributes, and provides support services of bone growth stimulator devices that enhance bone fusion. The Spinal Implants product category designs, develops, and markets a broad portfolio of motion preservation and fixation implant products used in surgical procedures of the spine. The Biologics product category provides a portfolio of regenerative products and tissue forms that allow physicians to treat a variety of spinal and orthopedic conditions. The Global Extremities reporting segment offers products and solutions that allow physicians to successfully treat a variety of orthopedic conditions unrelated to the spine. The company was founded on October 19, 1987 and is headquartered in Lewisville, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Orthofix and SeaSpine post mixed Q4 results, eye synergies and growth

SeaSpine and Orthofix reported mixed Q4 performances but demonstrated overall revenue growth for the full year, with positive revenue guidance for 2023.
The merger synergies and product demand strengths are key highlights, while challenges in profitability and regulatory hurdles in Europe require attention.
Opportunities lie in integration efforts, cost efficiencies, and exploring new markets, indicating a strategic growth trajectory for the combined entity.
The upcoming Analyst Teach-In event and focus on operational planning underscore the commitment to transparency and strategic alignment post-merger.

Orthofix reports robust Q1 earnings, raises full-year revenue guidance

Orthofix International's Q1 2023 earnings call highlighted strong financial performance, strategic initiatives, and raised revenue guidance, underscoring growth prospects.
The company's focus on operational efficiency, product categories, and profitability signals a resilient business strategy amidst market challenges and competitive landscape.
With a robust financial foundation, Orthofix is well-positioned to navigate challenges, capitalize on growth opportunities, and drive sustainable value creation for shareholders.

Orthofix International reports robust Q2 earnings and growth outlook

Orthofix International delivered a strong Q2 performance, with notable revenue growth and positive outlook for 2023.
Efforts to integrate merged businesses are yielding results, with a focus on revenue enhancement and operational streamlining.
Challenges such as cash flow and supply chain disruptions are being addressed through strategic investments and operational improvements.
The company's focus on growth, efficiency, and strategic partnerships positions it well for future success and value creation.

Orthofix reports robust Q3 revenue growth, eyes profitability and stability

Orthofix International demonstrated strong revenue growth and market performance in Q3 2023, driven by successful product lines and strategic initiatives.
While facing challenges such as cash flow outflows and margin adjustments, the company remains focused on profitability and financial stability.
Opportunities lie in sustaining positive momentum, achieving cash flow positivity in 2024, and leveraging growth prospects through product innovation and market expansion.

Orthofix reports robust Q4 earnings, eyes growth in key segments

Orthofix International's Q4 2023 earnings call highlighted strong financial performance, strategic initiatives, and growth in key segments.
The company's focus on market share, distributor relationships, and portfolio enhancements positions it well for future success.
Despite challenges in a competitive landscape, Orthofix remains optimistic about growth opportunities and aims for continued innovation and collaboration.

Orthofix International reports robust Q1 earnings and raises 2024 guidance

Orthofix International (OFIX) delivered a strong Q1 2024 performance, focusing on growth, innovation, and operational efficiency. The company showcased revenue growth, margin expansion, and strategic priorities for the year. Challenges include sustaining growth in competitive markets and optimizing operational aspects, while opportunities lie in leveraging technology and talent for further growth.

Orthofix International reports strong Q2 performance and outlines growth strategies

Orthofix International's Q2 performance reflects solid revenue growth and margin expansion, supported by new product releases and operational efficiency.
While facing challenges in cash flow optimization, the company's strategic focus on innovation and synergies positions it well for future growth.
Opportunities in technology investment, cross-selling, and distribution enhancements offer avenues for Orthofix International to drive sustained growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the third quarter ended September 30, 2020. Net sales were $111.0 million, earnings per share (“EPS”) was $0.24 and adjusted EPS was $0.31. “We are very pleased with our performance during the third quarter, which reflects continued strong execution and leadership as we navigate through the uncertainty of COVID, highlighted by 52% sequential global net sales growth over the second qu

Orthofix Reports Third Quarter 2020 Results

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal products and therapies, today announced that it plans to release financial results for the third quarter 2020 before market open on Thursday, November 5, 2020. Jon Serbousek, President and Chief Executive Officer, and Doug Rice, Chief Financial Officer, will host a conference call and webcast to review the Company's results at 8:30 a.m. ET the same day. Interested

Orthofix Schedules Third Quarter 2020 Earnings Release and Conference Call for November 5, 2020

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal healing products, today announced support for the U.S.

FDA Advisory Panel Recommends Pre-Market Clinical Evidence Requirement in Proposed Reclassification of Bone Growth Stimulators

CACI

ePlus

Systemax

TEGNA

Investors continue to hope for a generous fiscal package to tackle the pandemic, but remain cautious of the developments so far as the process has become highly politicized. Our deep learning algorithms have used AI to identify several Top Buys today if you are looking for places to invest.

Top Stocks To Buy Today As Markets Trade Flat Amid Low Unemployment Claims

Orthofix Medical, Inc. (OFIX) CEO Jon Serbousek on Q2 2020 Results - Earnings Call Transcript

Orthofix (OFIX) delivered earnings and revenue surprises of 26.25% and 35.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Orthofix (OFIX) Reports Q2 Loss, Tops Revenue Estimates

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the second quarter ended June 30, 2020.

Orthofix Reports Second Quarter 2020 Results

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today announced that President and Chief Executive Officer Jon Serbousek will present at the Canaccord Genuity 40th Annual Growth Conference on Thursday, August 13, 2020 at 2:30 p.m.

Orthofix to Present at the Canaccord Genuity Growth Conference on August 13

Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Orthofix (OFIX) Q2 Earnings Expected to Decline

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal products and therapies, today announced that it plans to release financial results for the second quarter 2020 before market open on Thursday, August 6, 2020.

Orthofix Schedules Second Quarter 2020 Earnings Release and Conference Call for August 6, 2020

Orthofix (OFIX) rides high on dual regulatory clearances for its deformity correction system, thus solidifying its pediatric orthopedics portfolio.

Orthofix JuniOrtho Plating System Gets Regulatory Clearances

Orthofix Medical, Inc. (OFIX) CEO Jon Serbousek on Q1 2020 Results - Earnings Call Transcript

Orthofix (OFIX) delivered earnings and revenue surprises of -18.18% and 0.31%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Orthofix (OFIX) Misses Q1 Earnings Estimates

ABIOMED

Becton, Dickinson and Co.

Amid the pandemonium on the account of coronavirus, we look into three stocks that have been struggling to cope with the scenario.

Coronavirus Hits Elective Procedures: 3 MedTech Stocks to Avoid

Orthofix (OFIX) pledges support for the continuation of the FDA's Class III status of BGS devices.

Orthofix Supports FDA Class III Label Continuation for BGS

We are upbeat about the year-over-year revenue growth recorded by majority of Orthofix's (OFIX) key operating segments in Q4.

Orthofix (OFIX) Q4 Earnings Match Estimates, Margins Decline

Orthofix Medical, Inc. (OFIX) CEO Jon Serbousek on Q4 2019 Results - Earnings Call Transcript

Orthofix (OFIX) delivered earnings and revenue surprises of 0.00% and -1.14%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Orthofix (OFIX) Q4 Earnings Match Estimates

Orthofix Medical, Inc. (OFIX) CEO Bradley Mason on Q3 2019 Results - Earnings Call Transcript

Orthofix (OFIX) delivered earnings and revenue surprises of -21.15% and -4.46%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Orthofix (OFIX) Q3 Earnings and Revenues Miss Estimates

Medtronic

Stryker

In the near future, there is a probability of 3D-printed implantable organs becoming a reality, thereby increasing the number of lives saved.

3D Printing Gaining Popularity: 3 MedTech Stocks to Watch

Orthofix Medical's (OFIX) Q2 performance across all business segments has been commendable, except for spinal implants.

Orthofix Medical (OFIX) Beats on Q2 Earnings, Margins Down

Orthofix Medical, Inc. (OFIX) CEO Bradley Mason on Q2 2019 Results - Earnings Call Transcript

Orthofix (OFIX) delivered earnings and revenue surprises of -30.00% and 0.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Orthofix (OFIX) Q2 Earnings Miss Estimates

BIOLASE

DexCom

Haemonetics

Lower investment in MedTech might prove to be a concern, more so as gains within this space are staggering.

News for Orthofix International Stock (OFIX)